Our results show that venetoclax-resistant AML cells accumulate metabolites associated with PI3K/AKT pathway activation, shift resistant AML MV4-11 cells towards glycolysis, and facilitate an increased redox potential, which ultimately favors resistance cell survival. This evidence concerns the gene AKT1 and acute myeloid leukemia.